An Analysis of Driving Performance Measures Used to Assess the Effects of Medications on Drowsiness, Sedation and Driving Impairment

The objective of this paper was to discuss driving scenarios and associated driving performance measures on their ability to demonstrate drowsiness, sedation, and driving impairment. The basis of this paper was a study that utilized a randomized, double-blind, double-dummy, four-treatment, four-period crossover trial in the Iowa Driving Simulator (IDS). Participants were 40 licensed drivers with seasonal allergic rhinitis who were 25 to 44 years of age. Treatments were Fexofenadine, diphenhydramine, alcohol, or placebo, given at weekly intervals before participants drove for 1 hour in the IDS. Measures examined included coherence, amplitude, phase angle, RMS error, following distance and behavior, lane keeping, response to unexpected vehicle intrusion and drowsiness. Study results show that sedating antihistamines impair driving performance as seriously as alcohol. Statistically significant but small correlations were found between subjective drowsiness and minimum following distance, steering instability, and left-lane excursions but no correlation was greater than 0.21. Drowsiness was a weak predictor of driving impairment. This paper discusses these and other finding with an emphasis on the adequacy of driving scenarios and the sensitivity of driving performance measures analyzed

Post-traumatic stress disorder following childbirth: an update of current issues and recommendations for future research

Objective: This paper aimed to report the current status of research in the field of post-traumatic stress disorder following childbirth (PTSD FC), and to update the findings of an earlier 2008 paper. Background: A group of international researchers, clinicians and service users met in 2006 to establish the state of clinical and academic knowledge relating to PTSD FC. A paper identified four key areas of research knowledge at that time. Methods: Fourteen clinicians and researchers met in Oxford, UK to update the previously published paper relating to PTSD FC. The first part of the meeting focused on updating the four key areas identified previously, and the second part on discussing new and emerging areas of research within the field. Results: A number of advances have been made in research within the area of PTSD FC. Prevalence is well established within mothers, several intervention studies have been published, and there is growing interest in new areas: staff and pathways; prevention and early intervention; impact on families and children; special populations; and post-traumatic growth. Conclusion: Despite progress, significant gaps remain within the PTSD FC knowledge base. Further research continues to be needed across all areas identified in 2006, and five areas were identified which can be seen as ‘new and emerging’. All of these new areas require further extensive research. Relatively little is still known about PTSD FC

The Grizzly, April 12, 2001

Airband 2001: \u27Case to the Ex\u27 Claims Victory • CAB, RHA, USGA and Class Officer Elections to be Held • Religion Forum Engages Students in Faith-based Discussion • The Big Test: Redefining the SATs • Opinions: Dispelling the Rumors: National Greeks Respond; Questioning the National Greek Approval Process; Purpose of Nationals: To Build up, not Destroy, Existing Greek Life on Campus; Why I Wanted to Bring Tri Sigma to Ursinus College; Tri Sigma Sorority Members Respond to Controversy; Phi Kappa Sigma Fraternity: The Brotherhood of Gentlemen; Why AOL Instant Messenger Will be the Demise of Society • Berman Exhibit \u27Zelda: By Herself\u27 on Display Until Apr. 19 • Women\u27s LAX Remains Undefeated, in First Placehttps://digitalcommons.ursinus.edu/grizzlynews/1488/thumbnail.jp

The Effect of Sample Handling on Cross Sectional HIV Incidence Testing Results

To determine if mishandling prior to testing would make a sample from a chronically infected subject appear recently infected when tested by cross-sectional HIV incidence assays.Serum samples from 31 subjects with chronic HIV infection were tested. Samples were subjected to different handling conditions, including incubation at 4 °C, 25 °C and 37 °C, for 1, 3, 7 or 15 days prior to testing. Samples were also subjected to 1,3, 7 and 15 freeze-thaw cycles prior to testing. Samples were tested using the BED capture enzyme immuno assay (BED-CEIA), Vironostika-less sensitive (V-LS), and an avidity assay using the Genetic Systems HIV-1/HIV-2 plus O EIA (avidity assay).Compared to the sample that was not subjected to any mishandling conditions, for the BED-CEIA, V-LS and avidity assay, there was no significant change in test results for samples incubated at 4 °C or 25 °C prior to testing. No impact on test results occurred after 15 freeze-thaw cycles. A decrease in assay results was observed when samples were held for 3 days or longer at 37 °C prior to testing.Samples can be subjected up to 15 freeze-thaw cycles without affecting the results the BED-CEIA, Vironostika-LS, or avidity assays. Storing samples at 4 °C or 25 °C for up to fifteen days prior to testing had no impact on test results. However, storing samples at 37°C for three or more days did affect results obtained with these assays

Specificity of Four Laboratory Approaches for Cross-Sectional HIV Incidence Determination: Analysis of Samples from Adults with Known Nonrecent HIV Infection from Five African Countries

Assays to determine cross-sectional HIV incidence misclassify some individuals with nonrecent HIV infection as recently infected, overestimating HIV incidence. We analyzed factors associated with false-recent misclassification in five African countries. Samples from 2197 adults from Botswana, Kenya, South Africa, Tanzania, and Uganda who were HIV infected > 12 months were tested using the (1) BED capture enzyme immunoassay (BED), (2) avidity assay, (3) BED and avidity assays with higher assay cutoffs (BED+ avidity screen), and (4) multiassay algorithm (MAA) that includes the BED+ avidity screen, CD4 cell count, and HIV viral load. Logistic regression identified factors associated with misclassification. False-recent misclassification rates and 95% confidence intervals were BED alone: 7.6% (6.6, 8.8); avidity assay alone: 3.5% (2.7, 4.3); BED+ avidity screen: 2.2% (1.7, 2.9); and MAA: 1.2% (0.8, 1.8). The misclassification rate for the MAA was significantly lower than the rates for the other three methods (each p < 0.05). Misclassification rates were lower when the analysis was limited to subtype C-endemic countries, with the lowest rate obtained for the MAA [0.8% (0.2, 1.9)]. Factors associated with misclassification were for BED alone: country of origin, antiretroviral treatment (ART), viral load, and CD4 cell count; for avidity assay alone: country of origin; for BED+ avidity screen: country of origin and ART. No factors were associated with misclassification using the MAA. In a multivariate model, these associations remained significant with one exception: the association of ART with misclassification was completely attenuated. A MAA that included CD4 cell count and viral load had lower false-recent misclassification than the BED or avidity assays (alone or in combination). Studies are underway to compare the sensitivity of these methods for detection of recent HIV infection

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed patients with EGFR mutation-positive, advanced non-small-cell lung cancer received oral dacomitinib (45 mg once-daily [QD]), with stepwise toxicity-managing DR (30 and 15 mg QD) permitted. Results: Skin toxicities (62.7%) were the most common DR-leading AEs. The AE incidence and severity decreased following DRs. Initial plasma dacomitinib exposure (45 mg QD) was generally lower in patients remaining at 45 mg QD compared with dose-reducing patients. Median PFS and OS were similar in all dacomitinib-treated patients and dose-reducing patients. Conclusion: Tolerability-guided dose modifications enabled patients to continue with dacomitinib and benefit from PFS/OS improvement

Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies.

BACKGROUND: Whole-body magnetic resonance imaging is advocated as an alternative to standard pathways for staging cancer. OBJECTIVES: The objectives were to compare diagnostic accuracy, efficiency, patient acceptability, observer variability and cost-effectiveness of whole-body magnetic resonance imaging and standard pathways in staging newly diagnosed non-small-cell lung cancer (Streamline L) and colorectal cancer (Streamline C). DESIGN: The design was a prospective multicentre cohort study. SETTING: The setting was 16 NHS hospitals. PARTICIPANTS: Consecutive patients aged ≥ 18 years with histologically proven or suspected colorectal (Streamline C) or non-small-cell lung cancer (Streamline L). INTERVENTIONS: Whole-body magnetic resonance imaging. Standard staging investigations (e.g. computed tomography and positron emission tomography-computed tomography). REFERENCE STANDARD: Consensus panel decision using 12-month follow-up data. MAIN OUTCOME MEASURES: The primary outcome was per-patient sensitivity difference between whole-body magnetic resonance imaging and standard staging pathways for metastasis. Secondary outcomes included differences in specificity, the nature of the first major treatment decision, time and number of tests to complete staging, patient experience and cost-effectiveness. RESULTS: Streamline C - 299 participants were included. Per-patient sensitivity for metastatic disease was 67% (95% confidence interval 56% to 78%) and 63% (95% confidence interval 51% to 74%) for whole-body magnetic resonance imaging and standard pathways, respectively, a difference in sensitivity of 4% (95% confidence interval -5% to 13%; p = 0.51). Specificity was 95% (95% confidence interval 92% to 97%) and 93% (95% confidence interval 90% to 96%) respectively, a difference of 2% (95% confidence interval -2% to 6%). Pathway treatment decisions agreed with the multidisciplinary team treatment decision in 96% and 95% of cases, respectively, a difference of 1% (95% confidence interval -2% to 4%). Time for staging was 8 days (95% confidence interval 6 to 9 days) and 13 days (95% confidence interval 11 to 15 days) for whole-body magnetic resonance imaging and standard pathways, respectively, a difference of 5 days (95% confidence interval 3 to 7 days). The whole-body magnetic resonance imaging pathway was cheaper than the standard staging pathway: £216 (95% confidence interval £211 to £221) versus £285 (95% confidence interval £260 to £310). Streamline L - 187 participants were included. Per-patient sensitivity for metastatic disease was 50% (95% confidence interval 37% to 63%) and 54% (95% confidence interval 41% to 67%) for whole-body magnetic resonance imaging and standard pathways, respectively, a difference in sensitivity of 4% (95% confidence interval -7% to 15%; p = 0.73). Specificity was 93% (95% confidence interval 88% to 96%) and 95% (95% confidence interval 91% to 98%), respectively, a difference of 2% (95% confidence interval -2% to 7%). Pathway treatment decisions agreed with the multidisciplinary team treatment decision in 98% and 99% of cases, respectively, a difference of 1% (95% confidence interval -2% to 4%). Time for staging was 13 days (95% confidence interval 12 to 14 days) and 19 days (95% confidence interval 17 to 21 days) for whole-body magnetic resonance imaging and standard pathways, respectively, a difference of 6 days (95% confidence interval 4 to 8 days). The whole-body magnetic resonance imaging pathway was cheaper than the standard staging pathway: £317 (95% confidence interval £273 to £361) versus £620 (95% confidence interval £574 to £666). Participants generally found whole-body magnetic resonance imaging more burdensome than standard imaging but most participants preferred the whole-body magnetic resonance imaging staging pathway if it reduced time to staging and/or number of tests. LIMITATIONS: Whole-body magnetic resonance imaging was interpreted by practitioners blinded to other clinical data, which may not fully reflect how it is used in clinical practice. CONCLUSIONS: In colorectal and non-small-cell lung cancer, the whole-body magnetic resonance imaging staging pathway has similar accuracy to standard staging pathways, is generally preferred by patients, improves staging efficiency and has lower staging costs. Future work should address the utility of whole-body magnetic resonance imaging for treatment response assessment. TRIAL REGISTRATION: Current Controlled Trials ISRCTN43958015 and ISRCTN50436483. FUNDING: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 66. See the NIHR Journals Library website for further project information

Disclosure: Contemporary Drawing Interpreted, Emphasized, and Revealed

Show card for exhibition Disclosure. November 4 - 15, 2002.https://digitalcommons.udallas.edu/disclosure/1000/thumbnail.jp

The Grizzly, October 11, 2000

University Students Disappointed by Rally • Ruhe\u27s \u27Athens\u27 with Ursinus Faces is a Work of Art • Homecoming 2000: Alumni Remember Collegeville Days • Food Critics Speak up at Dining Services Meeting • New Prof. has Students all Shook up...Over Shakespeare?! • Brodbeck Residents Take it to Extreme • French Officials Approve Morning-After Pill • Should Patients\u27 Drug Use be Confidential? • Nearing Fall Break, Freshmen High on UC Experience • The Wrong-Way Geese • Best Buddies: Offering Friendship, Making a Difference • Opinions: New Breed of Grizzly at Ursinus College; Abortion Pill Provides Pause for Debate; Pro-Life Sends Wrong Message; Is Bioengineering Ethical?; Ursinus Students React to Israeli-PLO Clashes; Presidential Debate Shows Just how Mediocre Politics can be; Defending Al Gore • Battle of the Bands Rocks in Reimert • Harpoon Louie\u27s a World Away from Wismer • Poetry Slam on Campus in November • Bears Maul Blue Jays • Women\u27s Rugby Roughed Up by Hawks • Binge Drinking Growing Problem on College Campuses • Roofies: Date Rape Drug More Popular, Dangerous Than Ever • Men\u27s Soccer Downs Aggies • New Coaches Bring Promise to Programs • Matty Earns McIntyre Award • Lowell\u27s Lone Goal Leads Bears to OT win Over Davidson Coll. • Lady Bears Struggle to go on Offensive • Volleyball Stomps the Sciences; Drops two CC Matches • Annual Alumni Lacrosse Match Ends in tie • Leadership in Adventure: ESS Class Molds Leaders Through Sporthttps://digitalcommons.ursinus.edu/grizzlynews/1475/thumbnail.jp